BNTCNasdaqPharmaceutical PreparationsFiscal year ends June 30
Benitec Biopharma Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 14, 2026
$8.36+0.25 (+3.08%)
Close on Oct 19, 2026
- Market cap
- $413.29M
- P/E (TTM)
- –
- Dividend yield
- –
Benitec Biopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Benitec Biopharma | Industry median |
|---|---|---|
| Market Cap | $291.62M | $166.30M |
| Enterprise Value | $111.65M | $88.19M |
| PB Ratio | 1.65 | 2.03 |
| P/TBV Ratio | 1.65 | 2.29 |
Income (trailing twelve months)
| Measure | Benitec Biopharma | Industry median |
|---|---|---|
| Operating Income | -$51.19M | -$21.40M |
| Net Income | -$45.55M | -$22.46M |
| EBITDA | -$51.13M | -$16.91M |
| EPS (Diluted) | -$0.98 | -$0.83 |
Returns
| Measure | Benitec Biopharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -33.2% | -53.2% |
| Return on Assets (ROA) | -32.3% | -40.9% |
| Return on Capital Employed (ROCE) | -28.9% | -38.1% |
Balance sheet
| Measure | Benitec Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $179.97M | $61.43M |
| Net Cash (Debt) | $179.97M | $15.35M |
| Net Cash Per Share | $5.16 | $0.66 |
| Equity (Book Value) | $177.01M | $49.09M |
| Book Value Per Share | $5.07 | $1.37 |
| Tangible Book Value | $177.01M | $23.52M |
| Working Capital | $176.34M | $76.81M |
Financial position
| Measure | Benitec Biopharma | Industry median |
|---|---|---|
| Current Ratio | 34.00 | 3.34 |
| Quick Ratio | 33.68 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Benitec Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$16.52M | -$12.35M |
| Capital Expenditures | -$105.00K | -$1.08M |
| Free Cash Flow | -$16.62M | -$20.22M |
| FCF Per Share | -$0.48 | -$0.42 |
Efficiency
| Measure | Benitec Biopharma | Industry median |
|---|---|---|
| Profits Per Employee | -$1.90M | -$703.34K |
| Employee Count | 24 | 74 |
Dividends and yields
| Measure | Benitec Biopharma | Industry median |
|---|---|---|
| Earnings Yield | -15.6% | -23.3% |
| FCF Yield | -5.70% | -8.72% |
| Buyback Yield | -35.8% | -0.59% |
| Shareholder Yield | -35.8% | 0.00% |
Shares
| Measure | Benitec Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 34,882,700 | 58,127,000 |
| Shares Change (YoY) | 28.6% | 10.9% |
| Shares Change (QoQ) | 0.18% | 0.54% |
| Float | 7,159,750 | 49,136,700 |
| Shares Held by Insiders | 79.5% | 11.6% |
| Shares Held by Institutions | 99.4% | 59.4% |
Scores
| Measure | Benitec Biopharma | Industry median |
|---|---|---|
| Altman Z-Score | 29.32 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Benitec Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.